AquAdvantage salmon.
AquAdvantage
Keep Frankenfish off my Dish! a protesters sign read. Another, adorned with six red hearts, suggested that real people love real salmon. A couple of years ago, protests against the approval and sale of genetically modified salmon targeted the Food and Drug Administration and supermarket chains across the country, attempting to halt the approval and sale of the AquAdvantage salmonan Atlantic salmon modified with DNA from the Chinook salmon and the ocean pout. The borrowed genetic material lets the fish grow year-round and reach market size in half the time as its natural counterpart, but its also spurred passionate public debate.
In November 2015, the FDA approved the AquAdvantage salmon as the first genetically engineered animal for human consumption. According to the hype, the AquAdvantage salmon could help with reducing global hunger, decreasing the carbon footprint of aquaculture (the cultivation of fish and other aquatic life), and shoring up dwindling wild fish stock. The regulatory process behind the approval of the AquAdvantage salmon took almost 20 years.
But the approval was quickly followed by a flurry of controversy and charges of insufficient consideration of key issues. A consortium of environmental groups lead by Earthjustice and the Center for Food Safety sued the FDA for approving the AquAdvantage salmon, in their words, without considering or fullydisclosing the environmental and other risks of this unprecedented decision. Two months after the approval, Congress also threw a wrench in the works by adding a rider to a spending bill that tasked the FDA with spending not less than $150,000 to develop labeling and implement a program of consumer disclosure for the fish before it could be made available for sale. As a result the fish is not yet anywhere near U.S. dinner plates, caught up in a seemingly endless process of contestation, with no clear end in sight.
To many in bioscience and biotechnology circles, this is a case of politics contaminating science. In an open letter to President Obama in 2014, a group of concerned international scientists and global technology company executives argue this point:
These scientists and others offer a picture of a Manichean world divided into those who are for scientific and technological progress and those who are against ita representation of the world that we have been seeing more and more of lately in reports of a war on science. But drawing this line is dangerous. The real problem here is the regulatory process itself, which forces dissent to take the narrow form of challenges to scientific data and methodology and ignores other questions about whats at stake.
The FDA approval process for the AquAdvantage salmon took longer and included more opportunities for public comment than most products the FDA reviews. This unique openness to public input was balanced by a careful parsing of what counts as scientifically and contextually relevant and what does not. The agency received 38,000 comments in response to its draft assessment alone, but it determined that just 90 were worth considering. The remaining comments were discounted as irrelevant because they did not directly address the details of the regulation process, or they raised issues beyond the mandate of the agency. These disregarded comments focused on a wide range of concerns, including patenting and ownership regimes of seed and crops; how deploying genetically modified corn and soy would affect the United States image around the world; continuing failures of existing market configurations to address inequality and food distribution; and the long history of multinational corporations central to the commercialization of biotechnologies, such as Monsanto, intentionally obscuring the negative impacts of their chemical products and byproducts while undermining human health.
Your Cheat-Sheet Guide to Synthetic Biology
What Exactly Is Synthetic Biology? Its Complicated.
Can You Patent an Organism? The Synthetic Biology Community Is Divided.
The U.S. Regulations for Biotechnology Are Woefully Out of Date
Synthetic Biology and Queer Theory Are Cutting Down the Tree of Life You Learned About in School
Being Skeptical About Biotechnology Doesnt Make You Anti-Science
So the FDA is not the forum for deliberation on the meaning of giving entry to this new form of life into our environment, grocery stores, and dining rooms. But what is? The FDA approval process is the only existing avenue for public consideration of technological innovation of this kind. Accordingly, the agencys narrow reading of what kinds of input are relevant represents a significant dismissal of a broad range of relevant concerns.
Some might read the vast public preoccupation with a broad set of social, political, and economic issues as the contamination of science with politics. But I would suggest that this is actually a case of the reverse problem: seemingly endless conflict around the AquAdvantage salmon reflects the limitation of using narrow scientific terms to address questions of broad social, political, and economic significance. As things stand, the only legitimate way to engage in debates about the entry of the AquAdvantage salmon and other genetically modified organisms into our environments, meals, intellectual property regimes, and beyond is to contest its approval at the level of regulatory science. When the system asks the public to limit objections to narrow technical concerns, it undermines regulatory legitimacy and stultifies democratic debateand perhaps most importantly, it contributes to the problematic discourse around science itself. When our modes of public deliberation strictly define what counts as a legitimate view on these issues, we end up portraying a good portion of the population as against science, when that in fact could not be further from the truth.
The vast majority of people in the world, not being scientists or angel investors, have no say over the technological trajectories that will shape our world and our lives. We are instructed to continue funding basic science and patiently wait and watch as the world is transformed around us. Scientists often dismiss resistance to the AquAdvantage salmon and other biotechnologies as borne of scientific ignorance. But its a lot easier to understand peoples reluctance if you realize that the debate is about much broader questions than science alone can answer.
To position science on one side of these debates is not only patently false but detrimental to public discourse.
As the first genetically engineered animal developed for human consumption, the AquAdvantage salmon can be understood as an early form or precursor to products of more advanced practices of synthetic biology. Even as the power and precision of these techniques increases and the particular technical challenges associated with the salmon are left behind, the core issues and deep public resistance around the AquAdvantage salmon will likely persist and haunt continued efforts to reshape environments, economies, and human life through the biological sciences. Synthetic biology is billed as having the potential to transform the world in a way that will disrupt prevailing economic and geopolitical paradigms and reshape the very fabric of life. The one thing both sides of the fishy debate seem to agree on is that the AquAdvantage salmon is a pioneer technology, and what happens to this fish could set the stage for the role that biotechnology will play in our food system in the century to come. As one commentator opined for the New York Times:
This framing suggests that biotechnological innovation is a necessary and unmitigated good. But for many, the prospect of a world radically altered by biotechnology conjures past experiences in which scientific progress didnt go as plannedlike the devastation and political instability ushered in by nuclear weapons. Similarly, to some, a dam looks like progress, development, and economic prosperity. But to others, it looks like the violent end of a way of life, heralded by the destruction of ecosystems and entire species.
The debates over the AquAdvantage salmon arent narrow and technicaltheyre multifaceted, laden with questions of political, economic, and social values. They are about what kind of world we want to live in and what types of transformations are beneficial, desirable, and helpfuland for whom. To position science on one side of these debates is not only patently false but detrimental to public discourse and productive political deliberation.
Nonetheless, resistance to biotechnologies is often framed as a problem of the uneducated masses meddling in areas where they dont belong. The open letter to Obama by the concerned scientists and technologists, for example, claims:
Characterizing legitimate concerns about what kinds of technologies enter and help shape our world as anti-science is more likely to alienate than inspire everyday Americans to identify with this vision of what science can do, and to believe in it.
The long journey of the AquAdvantage salmon may turn out to have been a waste of time, energy, and resources on all sides, but perhaps we can make it productive in one way. Understanding the limitations of the process can help us think critically about how decision-making about synthetic biology going forward might be more open to a broader set of concerns and voices much earlier in the innovation process. The way forward is not drawing battle lines between those who are for or against science and closing down regulatory processes to all but the narrowest risk-based considerations. Rather, we should be forming and expanding spaces for a wide range of participants in creatively considering how to solve societys biggest challenges. We need new ways of thinking and talking about technological promise and possibility in the world that we live in.
This article is part of the synthetic biology installment of Futurography, a series in which Future Tense introduces readers to the technologies that will define tomorrow. Each month, well choose a new technology and break it down. Future Tense is a collaboration among Arizona State University, New America, and Slate.
Visit link:
Skepticism About Biotechnology Isn't Anti-Science - Slate Magazine
- Is Weakness In Bloomage BioTechnology Corporation Limited (SHSE:688363) Stock A Sign That The Market Could be ... - Simply Wall St - March 28th, 2024
- Insiders were the biggest winners as Beijing Bohui Innovation Biotechnology Group Co., Ltd.'s (SZSE:300318) market ... - Simply Wall St - March 28th, 2024
- Biotechnology CEO and inventor of SiriusXM Satellite Radio Martine Rothblatt to deliver graduation address to the ... - EurekAlert - March 28th, 2024
- 6 biotechnology universities in the UK leading the way for future talent - Labiotech.eu - March 28th, 2024
- Is Vera Therapeutics Inc (VERA) a Bad Choice in Biotechnology Wednesday? - InvestorsObserver - March 28th, 2024
- Is G1 Therapeutics Inc (GTHX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 28th, 2024
- The three-year underlying earnings growth at Anhui Anke Biotechnology (Group) (SZSE:300009) is promising, but the ... - Simply Wall St - March 28th, 2024
- Is Lyra Therapeutics Inc (LYRA) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 28th, 2024
- Should You Sell 4D Molecular Therapeutics Inc (FDMT) in Biotechnology Industry? - InvestorsObserver - March 28th, 2024
- SPMVV receives 47.9 lakh grant from the governments Department of Biotechnology - The Hindu - March 28th, 2024
- Where Does IGC Pharma Inc (IGC) Stock Fall in the Biotechnology Field After It Is Up 14.71% This Week? - InvestorsObserver - March 28th, 2024
- Report Lays Out Road Map to Transform Understanding of RNA and Invest in RNA Science and Biotechnology - National Academies of Sciences, Engineering,... - March 28th, 2024
- Is Akebia Therapeutics Inc (AKBA) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 28th, 2024
- Singapore and Indonesia to foster bilateralism in healthcare, digital health, and biotechnology - BSA bureau - March 28th, 2024
- Where Does Gossamer Bio Inc (GOSS) Stock Fall in the Biotechnology Field After It Is Lower By -14.07% This Week? - InvestorsObserver - March 28th, 2024
- Where Does Equillium Inc (EQ) Stock Fall in the Biotechnology Field After It Is Down -31.25% This Week? - InvestorsObserver - March 28th, 2024
- Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin - FDA.gov - January 14th, 2024
- An Introduction to Biotechnology - PMC - National Center for ... - January 14th, 2024
- Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Yahoo Finance - January 14th, 2024
- Digital Life Norway (DLN) Initiative to foster and boost transdisciplinary biotechnology research and innovation - Open Access Government - January 14th, 2024
- Is Elevation Oncology Inc (ELEV) a Bad Choice in Biotechnology Thursday? - InvestorsObserver - January 14th, 2024
- Is Cytokinetics, Inc. (CYTK) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 14th, 2024
- Is Regeneron Pharmaceuticals Inc (REGN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 14th, 2024
- Is Axsome Therapeutics Inc (AXSM) a Good Buy in the Biotechnology Industry? - InvestorsObserver - January 14th, 2024
- Where Does Immunovant Inc (IMVT) Stock Fall in the Biotechnology Field After It Is Higher By 11.63% This Week? - InvestorsObserver - January 14th, 2024
- Should Biotechnology Stock Harpoon Therapeutics Inc (HARP) Be in Your Portfolio Wednesday? - InvestorsObserver - November 24th, 2023
- Should Biotechnology Stock SpringWorks Therapeutics Inc (SWTX) Be in Your Portfolio Wednesday? - InvestorsObserver - November 24th, 2023
- Where Does Cassava Sciences Inc (SAVA) Stock Fall in the Biotechnology Field After It Has Fallen -1.24% This Week? - InvestorsObserver - November 24th, 2023
- Where Does Kalvista Pharmaceuticals Inc (KALV) Stock Fall in the Biotechnology Field After It Is Lower By -1.04% This Week? - InvestorsObserver - November 24th, 2023
- Should Biotechnology Stock Theravance Biopharma Inc (TBPH) Be in Your Portfolio Thursday? - InvestorsObserver - April 23rd, 2023
- Where Will Sana Biotechnology Inc (SANA) Stock Go Next After It Is Down 1.35% in a Week? - InvestorsObserver - April 23rd, 2023
- Where Does Novo Nordisk A/S (NVO) Stock Fall in the Biotechnology Field After It Has Fallen -1.71% This Week? - InvestorsObserver - April 23rd, 2023
- Where Does Seagen Inc (SGEN) Stock Fall in the Biotechnology Field After It Is Lower By -0.81% This Week? - InvestorsObserver - April 23rd, 2023
- MSc Admissions at Institute of Bioinformatics and Applied Biotechnology, Bengaluru - Mathrubhumi English - April 23rd, 2023
- What is Biotechnology? Definition, Types and Applications | TechTarget - March 28th, 2023
- Biotechnology - Applications of biotechnology | Britannica - March 28th, 2023
- Biotechnology | FAO | Food and Agriculture Organization of the United ... - March 28th, 2023
- What is Biotechnology? Types and Applications - Iberdrola - March 28th, 2023
- Should Biotechnology Stock Checkpoint Therapeutics Inc (CKPT) Be in Your Portfolio Monday? - InvestorsObserver - March 28th, 2023
- Where Does IGM Biosciences Inc (IGMS) Stock Fall in the Biotechnology Field After It Has Fallen -1.80% This Week? - InvestorsObserver - March 28th, 2023
- Is Day One Biopharmaceuticals Inc (DAWN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 28th, 2023
- Where Does Jasper Therapeutics Inc (JSPR) Stock Fall in the Biotechnology Field After It Has Risen 3.16% This Week? - InvestorsObserver - March 28th, 2023
- Is Evaxion Biotech A/S - ADR (EVAX) a Leader in the Biotechnology Industry? - InvestorsObserver - February 14th, 2023
- Where Does Oncolytics Biotech Inc (ONCY) Stock Fall in the Biotechnology Field After It Has Risen 1.72% This Week? - InvestorsObserver - February 14th, 2023
- Where Does Surrozen Inc (SRZN) Stock Fall in the Biotechnology Field After It Is Up 59.74% This Week? - InvestorsObserver - February 14th, 2023
- International Biotechnology Trust's Investment Manager to Focus on Core Healthcare Business - Marketscreener.com - February 14th, 2023
- Where Does Ocugen Inc (OCGN) Stock Fall in the Biotechnology Field After It Is Lower By -14.73% This Week? - InvestorsObserver - February 14th, 2023
- Is Protagonist Therapeutics Inc (PTGX) a Smart Choice in Biotechnology Friday? - InvestorsObserver - February 14th, 2023
- Where Does Kiora Pharmaceuticals Inc (KPRX) Stock Fall in the Biotechnology Field After It Has Risen 33.24% This Week? - InvestorsObserver - February 14th, 2023
- Where Does Novavax Inc (NVAX) Stock Fall in the Biotechnology Field After It Is Up 0.46% This Week? - InvestorsObserver - February 14th, 2023
- City of Vacaville Introduces Next Generation to Biotechnology and Advanced Manufacturing - Financial Post - February 6th, 2023
- Is Incyte Corporation (INCY) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - February 6th, 2023
- Where Does Catalyst Pharmaceuticals Inc (CPRX) Stock Fall in the Biotechnology Field After It Is Down -3.88% This Week? - InvestorsObserver - February 6th, 2023
- Where Does Summit Therapeutics Inc (SMMT) Stock Fall in the Biotechnology Field After It Is Up 8.63% This Week? - InvestorsObserver - February 6th, 2023
- Where Does Compass Therapeutics Inc. (CMPX) Stock Fall in the Biotechnology Field After It Is Down -2.89% This Week? - InvestorsObserver - February 6th, 2023
- Should You Be Impressed By Puma Biotechnology, Inc.'s (NASDAQ:PBYI) ROE? - Simply Wall St - January 21st, 2023
- Where Does Palisade Bio Inc (PALI) Stock Fall in the Biotechnology Field After It Is Lower By -11.27% This Week? - InvestorsObserver - January 21st, 2023
- Is Autolus Therapeutics PLC (AUTL) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 21st, 2023
- Where Does Edesa Biotech Inc (EDSA) Stock Fall in the Biotechnology Field After It Has Fallen -39.16% This Week? - InvestorsObserver - January 21st, 2023
- Where Does Vaxcyte Inc (PCVX) Stock Fall in the Biotechnology Field After It Has Fallen -7.21% This Week? - InvestorsObserver - January 12th, 2023
- Where Does CytomX Therapeutics Inc (CTMX) Stock Fall in the Biotechnology Field After It Is Up 61.68% This Week? - InvestorsObserver - January 12th, 2023
- Where Does Vyant Bio Inc (VYNT) Stock Fall in the Biotechnology Field After It Is Up 36.36% This Week? - InvestorsObserver - January 12th, 2023
- Is CTI BioPharma Corp (CTIC) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 12th, 2023
- Where Does Jaguar Health Inc (JAGX) Stock Fall in the Biotechnology Field After It Has Gained 22.22% This Week? - InvestorsObserver - January 12th, 2023
- Where Does Geron Corporation (GERN) Stock Fall in the Biotechnology Field After It Has Gained 9.09% This Week? - InvestorsObserver - January 12th, 2023
- Is OncoSec Medical Inc (ONCS) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 12th, 2023
- What is Biotechnology? Master of Biotechnology - January 4th, 2023
- Where Does Chemomab Therapeutics Ltd - ADR (CMMB) Stock Fall in the Biotechnology Field After It Has Gained 52.97% This Week? - InvestorsObserver - January 4th, 2023
- Should Biotechnology Stock Galera Therapeutics Inc (GRTX) Be in Your Portfolio Wednesday? - InvestorsObserver - January 4th, 2023
- Where Does 180 Life Sciences Corp (ATNF) Stock Fall in the Biotechnology Field After It Is Lower By -26.07% This Week? - InvestorsObserver - January 4th, 2023
- Is Adaptive Biotechnologies Corp (ADPT) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 4th, 2023
- Is ImmunoGen, Inc. (IMGN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 4th, 2023
- Is DBV Technologies SA - ADR (DBVT) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 4th, 2023
- Does PDS Biotechnology Corp (PDSB) Have What it Takes to be in Your Portfolio Wednesday? - InvestorsObserver - December 27th, 2022
- Where Does Intercept Pharmaceuticals Inc (ICPT) Stock Fall in the Biotechnology Field After It Is Lower By -10.50% This Week? - InvestorsObserver - December 27th, 2022
- Where Does Merrimack Pharmaceuticals Inc (MACK) Stock Fall in the Biotechnology Field After It Has Fallen -10.39% This Week? - InvestorsObserver - December 27th, 2022
- Where Does Compass Therapeutics Inc. (CMPX) Stock Fall in the Biotechnology Field After It Is Higher By 2.68% This Week? - InvestorsObserver - December 27th, 2022
- Where Does Allogene Therapeutics Inc (ALLO) Stock Fall in the Biotechnology Field After It Is Lower By -19.38% This Week? - InvestorsObserver - December 27th, 2022
- Where Does Oramed Pharmaceuticals, Inc. (ORMP) Stock Fall in the Biotechnology Field After It Is Higher By 11.42% This Week? - InvestorsObserver - December 27th, 2022
- Is Calithera Biosciences Inc (CALA) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - December 27th, 2022